Baseline characteristics of the Ibr-treated cohort
| Characteristics . | N = 119 . |
|---|---|
| Age, median (range) | 80 (80-87) |
| CIRS >6, n (%) | 69 (58) |
| TP53 disruption, n (%) | 61 (51) |
| Del(17p), n (%) | 40 (34) |
| TP53 mutation, n (%) | 47 (40) |
| Missing data, n (%) | 6 (5) |
| IGHV unmutated, n (%) | 61 (51) |
| CrCl < 60 mL/min, n (%) | 79 (66) |
| Binet stages | |
| A, (%) | 11 (9) |
| B, (%) | 53 (45) |
| C, (%) | 55 (46) |
| Treatment naïve, n (%) | 79 (66) |
| Relapsed patients, n (%) | 40 (34) |
| Previous lines, median (range) | 0 (0-8) |
| 1, n (%) | 20 (17) |
| 2, n (%) | 10 (8) |
| 3+, n (%) | 10 (8) |
| Type of previous therapy | |
| Chlorambucil ± anti-CD20, n (%) | 24 (20) |
| FC-R, BR, n (%) | 26 (22) |
| Others (lenalidomide, rituximab, CHOP, RCVP, alemtuzumab, idelalisib-R), n (%) | 17 (14) |
| Efficacy (best response) | |
| ORR (CR + CRi + PR + PR-L), n (%) | 107 (90) |
| SD, n (%) | 12 (10) |
| PD, n (%) | 0 (0) |
| Richter transformation, n (%) | 7 (6) |
| Characteristics . | N = 119 . |
|---|---|
| Age, median (range) | 80 (80-87) |
| CIRS >6, n (%) | 69 (58) |
| TP53 disruption, n (%) | 61 (51) |
| Del(17p), n (%) | 40 (34) |
| TP53 mutation, n (%) | 47 (40) |
| Missing data, n (%) | 6 (5) |
| IGHV unmutated, n (%) | 61 (51) |
| CrCl < 60 mL/min, n (%) | 79 (66) |
| Binet stages | |
| A, (%) | 11 (9) |
| B, (%) | 53 (45) |
| C, (%) | 55 (46) |
| Treatment naïve, n (%) | 79 (66) |
| Relapsed patients, n (%) | 40 (34) |
| Previous lines, median (range) | 0 (0-8) |
| 1, n (%) | 20 (17) |
| 2, n (%) | 10 (8) |
| 3+, n (%) | 10 (8) |
| Type of previous therapy | |
| Chlorambucil ± anti-CD20, n (%) | 24 (20) |
| FC-R, BR, n (%) | 26 (22) |
| Others (lenalidomide, rituximab, CHOP, RCVP, alemtuzumab, idelalisib-R), n (%) | 17 (14) |
| Efficacy (best response) | |
| ORR (CR + CRi + PR + PR-L), n (%) | 107 (90) |
| SD, n (%) | 12 (10) |
| PD, n (%) | 0 (0) |
| Richter transformation, n (%) | 7 (6) |
BR, bendamustine-rituximab; CHOP, cyclophosphamide doxorubicine vincristine and prednisolone; CrCl, creatinine clearance; CRi, complete response with incomplete count recovery; FC-R, ludarabine, cyclophosphamide and rituximab; idelalisib-R, idelalisib, rituximab; PD, progressive disease; PR, partial response; PR-L, partial response with lymphocytosis; RCVP, rituximab, cyclophosphamide, vincristine and prednisolone; SD, stable disease.